Source comparison
The Mechanistic Difference: Upstream Stimulation vs Direct Replacement
Synthetic HGH (somatropin) is bioidentical to the 191-amino-acid polypeptide your pituitary naturally secretes. But when you inject it subcutaneously, you're bypassing the entire hypothalamic-pituitary axis. The exogenous hormone floods GH receptors in the liv
This comparison does not assign a generated winner or score.
- Synthetic HGH (somatropin) is bioidentical to the 191-amino-acid polypeptide your pituitary naturally secretes. But when you inject it subcutaneously, you're bypassing the entire hypothalamic-pituitary axis. The exogenous hormone floods GH receptors in the liver, muscle, and adipose tissue, triggering IGF-1 production and all the downstream anabolic effects HGH produces. But here's what doesn't happen: your pituitary stops secreting its own growth hormone. The body detects supraphysiological GH levels through negative feedback loops mediated by IGF-1 and somatostatin, and somatotroph cells in the anterior pituitary downregulate production. Over time. Typically 8–12 weeks of continuous exogenous HGH administration. Endogenous GH secretion can be suppressed by 70–90%, creating a dependence on the synthetic hormone.
- Sermorelin works one step earlier in the cascade. It's a 29-amino-acid fragment of the full 44-amino-acid GHRH molecule, containing the bioactive segment that binds to GHRH receptors on somatotroph cells. When you administer sermorelin subcutaneously, it crosses into systemic circulation, reaches the anterior pituitary, and binds to those receptors. Signaling the cells to release stored growth hormone. The key difference: the pituitary releases GH in a pulsatile pattern, mimicking the natural circadian rhythm of GH secretion that peaks during deep sleep. This pulsatility preserves the feedback regulation that synthetic HGH disrupts. IGF-1 levels rise in response to the GH pulse, somatostatin is released to terminate the pulse, and the system resets. The pituitary remains responsive. It doesn't shut down.
- Our experience with research-grade Real peptides shows that protocols using GHRH analogues maintain pituitary responsiveness across 12–16 week cycles, while synthetic HGH protocols at equivalent IGF-1 endpoints consistently suppress endogenous secretion within 6–8 weeks.